B. Kagina

发表

Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes

Robert M. DiFazio, Louis R. Joslyn, D. Kirschner, 2018, Front. Microbiol..

Specific T cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis, Following BCG Vaccination of Newborns

G. Kaplan, M. Hatherill, T. Scriba, 2010 .

Association between BCG-induced immunity and risk of TB disease

B. Kagina, 2011 .

Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease.

T. Scriba, G. Hussey, W. Hanekom, 2010, Vaccine.

Human newborn bacille Calmette–Guérin vaccination and risk of tuberculosis disease: a case-control study

G. Kaplan, R. Sékaly, M. Hatherill, 2016, BMC Medicine.

Metabolite changes in blood predict the onset of tuberculosis

Michel R. Klein, Jane Hughes, Gerhard Walzl, 2018, Nature Communications.

Safety and Immunogenicity of H1/IC31H, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

T. Scriba, W. Hanekom, K. Reither, 2015 .

Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

T. Scriba, W. Hanekom, K. Reither, 2014, PloS one.

Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.

T. Scriba, W. Hanekom, N. Kiwanuka, 2014, The Journal of infectious diseases.

Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response.

T. Scriba, G. Hussey, W. Hanekom, 2009, Vaccine.

H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.

M. Hatherill, T. Scriba, W. Hanekom, 2017, Vaccine.

A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe

M. Tameris, M. Hatherill, T. Scriba, 2015, Vaccine.

Characterisation of National Immunisation Programmes (NIPs) in the context of Public Health Emergencies (PHEs): A Case Study of 13 Countries in the WHO African Region

B. Kagina, E. Amponsah-Dacosta, Viola Chepkurui, 2020 .

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

M. Tameris, M. Hatherill, T. Scriba, 2015, Vaccine.

Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis

M. Hatherill, T. Scriba, S. Mbandi, 2020, PloS one.

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.

G. Kaplan, M. Hatherill, T. Scriba, 2010, American journal of respiratory and critical care medicine.

Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells

U. Certa, K. Reither, P. Andersen, 2015, Clinical and Vaccine Immunology.

T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection

G. Schoolnik, F. Miedema, D. Tabb, 2023, Nature Medicine.

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.

M. Tameris, M. Hatherill, T. Scriba, 2014, Vaccine.

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

E. V. van Rikxoort, E. Bateman, J. Goldin, 2017, American journal of respiratory and critical care medicine.

RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

Daniel E. Zak, D. Zak, G. Schoolnik, 2020, Scientific Reports.

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.

G. Kaplan, T. Scriba, G. Hussey, 2015, Journal of immunological methods.

Characterization of National Immunization Programs in the Context of Public Health Emergencies: A Case Study of 13 Countries in the WHO Africa Region

B. Kagina, E. Amponsah-Dacosta, E. Haddison, 2021, Frontiers in Public Health.

Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood

Elisa Nemes, T. Scriba, W. Hanekom, 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial

M. Tameris, M. Hatherill, T. Scriba, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol

M. Hatherill, T. Scriba, S. Mbandi, 2019, BMJ Open.

Interventions to Improve Knowledge, Attitudes, and Uptake of Recommended Vaccines during Pregnancy and Postpartum: A Scoping Review

B. Kagina, R. Muloiwa, E. Amponsah-Dacosta, 2023, Vaccines.